Report from the International Dermatology Outcome Measures Initiative

Overview

Journal J Investig Dermatol Symp Proc

Publisher Elsevier

Specialty Dermatology

Date 2020 Oct 25

PMID 33099394

Citations 1

Authors

Lourdes M Perez-Chada

Joseph F Merola

April W Armstrong

Amit Garg

John Latella

Alice B Gottlieb

Affiliations

Soon will be listed here.

Abstract

The International Dermatology Outcome Measures is a nonprofit organization dedicated to developing evidence-based, patient-centered outcome measures for dermatologic conditions. At the 2018 Alopecia Areata Research Summit, Dr Gottlieb, President of the International Dermatology Outcome Measures, presented an overview of their work in psoriasis, hidradenitis suppurativa, acne, and eczema and discussed the potential areas of mutual interest with the National Alopecia Areata Foundation. Herein, we present a summary of the topics discussed.

Citing Articles

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments.

Blome C, Augustin M, Klein T Am J Clin Dermatol. 2021; 22(6):747-755.

PMID: 34383273 PMC: 8566428. DOI: 10.1007/s40257-021-00622-7.

References

Gottlieb A, Armstrong A, Christensen R, Garg A, Callis Duffin K, Boehncke W . The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. J Rheumatol. 2014; 41(6):1227-9. DOI: 10.3899/jrheum.140176. View

Sisic M, Kirby J, Boyal S, Plant L, McLellan C, Tan J . Development of a Quality-of-Life Measure for Hidradenitis Suppurativa. J Cutan Med Surg. 2016; 21(2):152-155. PMC: 5520966. DOI: 10.1177/1203475416677721. View

Gottlieb A, Salame N, Armstrong A, Merola J, Parra S, Takeshita J . A provider global assessment quality measure for clinical practice for inflammatory skin disorders. J Am Acad Dermatol. 2018; 80(3):823-828. DOI: 10.1016/j.jaad.2018.09.017. View

Boers M, Kirwan J, Wells G, Beaton D, Gossec L, DAgostino M . Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014; 67(7):745-53. DOI: 10.1016/j.jclinepi.2013.11.013. View

Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O . Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014; 66(12):1759-66. PMC: 4282108. DOI: 10.1002/acr.22404. View

Gottlieb A, Levin A, Armstrong A, Abernethy A, Callis Duffin K, Bhushan R . The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol. 2014; 72(2):345-8. DOI: 10.1016/j.jaad.2014.11.002. View

Kavanaugh A, Helliwell P, Ritchlin C . Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther. 2016; 3(1):91-102. PMC: 4999579. DOI: 10.1007/s40744-016-0029-z. View

Porter M . What is value in health care?. N Engl J Med. 2010; 363(26):2477-81. DOI: 10.1056/NEJMp1011024. View

Thorlacius L, Ingram J, Villumsen B, Esmann S, Kirby J, Gottlieb A . A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018; 179(3):642-650. PMC: 6141318. DOI: 10.1111/bjd.16672. View

10.

Riis P, Vinding G, Ring H, Jemec G . Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D. Acta Derm Venereol. 2015; 96(2):222-6. DOI: 10.2340/00015555-2129. View

11.

Boers M, Brooks P, Strand C, Tugwell P . The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol. 1998; 25(2):198-9. View

12.

Prinsen C, Vohra S, Rose M, Boers M, Tugwell P, Clarke M . How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" - a practical guideline. Trials. 2016; 17(1):449. PMC: 5020549. DOI: 10.1186/s13063-016-1555-2. View

13.

Perez-Chada L, Cohen J, Gottlieb A, Callis Duffin K, Garg A, Latella J . Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Arch Dermatol Res. 2018; 310(9):701-710. DOI: 10.1007/s00403-018-1855-3. View

14.

Salame N, Perez-Chada L, Singh S, Callis Duffin K, Garg A, Gottlieb A . Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. Dermatology. 2018; 234(5-6):157-165. DOI: 10.1159/000490413. View

15.

Shikiar R, Rentz A . Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health. 2004; 7(2):204-15. DOI: 10.1111/j.1524-4733.2004.72252.x. View

16.

Ogdie A, Weiss P . The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015; 41(4):545-68. PMC: 4610151. DOI: 10.1016/j.rdc.2015.07.001. View

17.

Callis Duffin K, Merola J, Christensen R, Latella J, Garg A, Gottlieb A . Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. JAMA Dermatol. 2018; 154(10):1137-1144. PMC: 6233740. DOI: 10.1001/jamadermatol.2018.1165. View

18.

Porter M, Larsson S, Lee T . Standardizing Patient Outcomes Measurement. N Engl J Med. 2016; 374(6):504-6. DOI: 10.1056/NEJMp1511701. View

19.

Thorlacius L, Ingram J, Garg A, Villumsen B, Esmann S, Kirby J . Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open. 2017; 7(2):e014733. PMC: 5337705. DOI: 10.1136/bmjopen-2016-014733. View

20.

Williamson P, Altman D, Bagley H, Barnes K, Blazeby J, Brookes S . The COMET Handbook: version 1.0. Trials. 2017; 18(Suppl 3):280. PMC: 5499094. DOI: 10.1186/s13063-017-1978-4. View